Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Room For More? Karyopharm Targets Highly Refractory Myeloma Patients

Executive Summary

Crowded field of multiple myeloma has yet another contender – Karyopharm's first-in-class SIN/XPO1 antagonist selinexor – but company thinks "penta-refractory" approach will be a good calling card.

You may also be interested in...

Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers

Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.

Multiple Myeloma Market Snapshot: New Drugs And Big Changes

The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts